Showing 5781-5790 of 10903 results for "".
Navigating Practice: Tips from the DEF Webinar Series
https://practicaldermatology.com/conferences/conference-coverage-def/navigating-practice-tips-from-the-def-webinar-series/23301/From skin signs of COVID-19 to strategies for optimizing telehealth, experts shared strategies to support NPs and PAs.EHR User Series—Part III
https://practicaldermatology.com/topics/practice-management/ehr-user-seriespart-iii/21509/A Q&A series with clinicians about their experience and broader impressions of EHRs in dermatology.Marketing Leading Technologies That Support Your Team
https://practicaldermatology.com/issues/august-2025/marketing-leading-technologies-that-support-your-team/36708/From ChatGPT and other artificial intelligence (AI) platforms to the latest mobile apps, technology continues to transform the already dynamic field of health care.How Will Dermatologists Use ChatGPT?
https://practicaldermatology.com/topics/practice-management/how-will-dermatologists-use-chatgpt/23876/Dr. Patel explores the potential role of ChatGPT in clinical practice and academics.Eight Internet Marketing Trends Dermatology Marketers Should Follow in 2018
https://practicaldermatology.com/topics/practice-management/eight-internet-marketing-trends-dermatology-marketers-should-follow-in-2018/20498/Some vital trends may develop in 2018 to impact your dermatology marketing strategy.The Google+ Hangout: A Marketing Tool For Your Dermatology Practice
https://practicaldermatology.com/topics/practice-management/the-google-hangout-a-marketing-tool-for-your-dermatology-practice/21423/Dermatology marketers can employ this tool effectively to promote their practices or simply use it as a powerful and free communication tool.Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manSelecting the Optimal JAK Inhibitor for Alopecia Areata
https://practicaldermatology.com/topics/hair-nails/selecting-the-optimal-jak-inhibitor-for-alopecia-areata/67265/Since 2022, the US Food and Drug Administration (FDA) has approved three oral JAK inhibitors: baricitinib, ritlecitinib, and deuruxolitinib.Stevens-Johnson Syndrome: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/stevens-johnson-syndrome-a-case-series/23902/Successful treatment of drug-induced Stevens-Johnson Syndrome using cyclosporine and etanercept.Prescribing Pitfalls Part II: Techniques for Prescribing Success
https://practicaldermatology.com/topics/practice-management/prescribing-pitfalls-part-ii-techniques-for-prescribing-success/21413/Simple strategies employed in the office can improve the likelihood of treatment success and enhance patient satisfaction.